Abstract
Phyllanthus niruri L. (Phyllanthaceae), commonly known as Bhui Amla, is used as a traditional medicine in the Asian region. This review provides an overview of the therapeutic potential of P. niruri in the management of obesity, dyslipidemia, diabetes, hepatic disorders, chronic kidney disease (CKD), and inflammation. P. niruri plays a crucial role in obesity and hyperlipidemia by reducing body weight, visceral fat accumulation, serum cholesterol, triglycerides, low-density lipoprotein levels, and insulin resistance. On the contrary, it improves an individual's antioxidant status and lipid profile. Additionally, improved renal biomarkers, suppression of inflammatory biomarkers, and reduced fibrosis are signs of the renoprotective effects of Phyllanthus niruri. Furthermore, P. niruri demonstrates hepatoprotective and antifibrotic properties. Lowering liver enzyme levels, improving lipid metabolism, reducing inflammatory cytokines, and restoring normal hepatic architecture across various models of liver injury are signs of hepatoprotective and antifibrotic effects. Also show anti-inflammatory activities such as inhibition of edema formation, suppression of pro-inflammatory cytokines, and modulation of oxidative stress pathways. Clinical studies further support its safety and efficacy, particularly in liver diseases.
Cite
- MLA: Talukder, R.; Ghosh, D.; Boshra, K.; Saha, B.; Salehin, M. U.; Islam, F. W.; Saffoon, N.; Alam, M. A.. "A review on the potential therapeutic effect of Phyllanthus niruri on Obesity and its related complication." J. Bio. Exp. Pharm 4.1 (2026): 01-36.
- APA: Talukder, R.; Ghosh, D.; Boshra, K.; Saha, B.; Salehin, M. U.; Islam, F. W.; Saffoon, N.; Alam, M. A., (2026). A review on the potential therapeutic effect of Phyllanthus niruri on Obesity and its related complication. J. Bio. Exp. Pharm, 4(1), 01-36.
- Chicago: Talukder, R.; Ghosh, D.; Boshra, K.; Saha, B.; Salehin, M. U.; Islam, F. W.; Saffoon, N.; Alam, M. A.. "A review on the potential therapeutic effect of Phyllanthus niruri on Obesity and its related complication." J. Bio. Exp. Pharm 4, no. 1 (2026): 01-36.
- Harvard: Talukder, R.; Ghosh, D.; Boshra, K.; Saha, B.; Salehin, M. U.; Islam, F. W.; Saffoon, N.; Alam, M. A., 2026. A review on the potential therapeutic effect of Phyllanthus niruri on Obesity and its related complication. J. Bio. Exp. Pharm, 4(1), pp.01-36.
- Vancouver: Talukder, R.; Ghosh, D.; Boshra, K.; Saha, B.; Salehin, M. U.; Islam, F. W.; Saffoon, N.; Alam, M. A.. A review on the potential therapeutic effect of Phyllanthus niruri on Obesity and its related complication. J. Bio. Exp. Pharm. 2026;4(1):01-36.
Keywords
1. Introduction
Phyllanthus niruri L., in the genus Phyllanthus and family Phyllanthaceae, is a widely distributed tropical plant commonly found in coastal areas. This plant is found in Texas, Mexico, Central America, and vast regions of South America. It is also distributed in Africa, Asia, Australia, and Oceania, including wastelands and other areas. In Spanish, it is commonly known as chanca piedra. [1]. Phyllanthus niruri is a terminal herbaceous plant, typically 30- 60 cm tall, with a characteristic phyllanthoid branching pattern in which various branchlets and leaf-like, compound leaves develop due to the quick abscission of leaves on the main stem. The main stem is smooth, cylindrical (terete), and hairless (glabrous), approximately 1–2.5 mm in diameter. The stem and its branches are light green to reddish in color [2].
The crude extract of the whole plant or its Herbal Brews as a tea (Standard traditional dosage range is 1-2 grams) has been used in traditional medicine[3]. Phyllanthus niruri has been widely used in traditional, complementary, and integrative medicine (TCIM) to treat digestive problems, liver, kidney, and urinary conditions [3].
In Ayurveda, Phyllanthus niruri is known as “bhumi amla” [4]. Worldwide, it has been widely used in traditional, complementary, and integrative medicine (TCIM) systems to treat a range of medical conditions, including digestive problems and liver, kidney, and urinary conditions [3]. Traditionally, it has been used as a diuretic and antilithic agent, which aids in dissolving kidney stones and provides protection from urinary calculi [4,5]. In ancient India, this plant has been used to treat jaundice, hepatitis, fever, spleen disorders, and liver inflammation; in traditional Chinese medicine, it has been used as a diuretic, to support liver health, and to promote detoxification [3].
Phyllanthus niruri exhibits pharmacological actions to reduce fatty liver disease, including liver cirrhosis, diabetes mellitus, obesity, and dyslipidemia [4]. In Ayurveda, juice or powder from Phyllanthus niruri is used to treat viral infections and reduce bile production [6].
In traditional Malay medicine, Phyllanthus niruri is also used to manage diabetes, fever, wound healing, tissue repair, postpartum recovery, and gastrointestinal problems, including antiulcer effects. In Africa, specifically in Nigeria, Ghana, and Congo, it is used against fevers, infections, and malaria [3, 6,7].
2. Methodology
This review was conducted to evaluate the therapeutic effects of Phyllanthus niruri on obesity and dyslipidemia, diabetes, hepatic disorders, chronic kidney disease, and inflammation. This comprehensive literature review covers 10 years (2015-2025) of relevant articles, using online databases such as PubMed, Scopus, Google Scholar, ScienceDirect, and Web of Science. Keywords such as “Phyllanthus niruri,” “obesity,” “dyslipidemia,” “diabetes,” “chronic kidney disease,” “renal protection,” “hepatic fibrosis,” “hepatoprotective,” “inflammation,” “antioxidant,” and “clinical trial” were used while searching for relevant articles.
This review article uses a table format to organize all the extracted data, such as study design, experimental model, dosage, treatment duration, biomarkers assessed, molecular targets, histopathological findings, and major therapeutic outcomes, to ease reading & skimming of the selected relevant articles and uses EndNote software for referencing.
3. Role of Phyllanthus niruri in Obesity and Dyslipidemia
Table 1: Effects of Phyllanthus niruri on obesity and dyslipidemia in preclinical studies
|
Experimental Model |
Dose & Duration |
Result/ Findings |
Ref. |
|
HFD-induced male Sprague-Dawley rats |
8 weeks |
↓ B.wt ↓TC, TG, ALT, AST, LDL, HDL, glucose, leptin, adipocyte size levels |
[20] |
|
HFD- induced male Sprague dawley rats |
1000mg/kg body weight in 4 weeks |
↑Adiponectin ↓Hepatic micro -macro steatosis and fibrosis ↓TNF-α, IL-6, RBP4, Vaspin, Progranulin ↓PPARγ , SLC10A2, Collagen-1α levels ↓Microvessel growth, endothelial cell migration, tube formation and VEGF secretion
|
[21] |
|
MCDM induced Sprague Dawley rats |
0.3, 3, 30 µg/mL 72 hours incubation in MCDM |
↓ Lipid accumulation, AST, ROS, Inflammation (NF-κB) levels ↑ Lipolysis, GSH, Mitochondrial potential levels Normalized stress genes (FGF21, FXR, CHOP, CXCL5)
|
[22] |
|
HFD-induced male albino rats |
250 mg/kg b.wt for 105 days |
↓ ALT, AST, ALP, levels ↑HDL, TP, albumin, A/G ratio levels ↓TC, TG, LDL-C, VLDL-C levels ↓Blood glucose, insulin, HOMA-IR, HOMA-β levels ↓Serum C3 Reduced micro steatosis, inflammation and necrotic hepatocyte
|
[23]
|
|
Aspartame (ASP) induced in female Swiss albino mice |
40 mg/kg for 30 days and 60 days |
↓ B.wt and O.wt ↓ ASP, TGs, ALP, AST, LDH, TGs levels ↓ROS level
|
[24] |
|
(DEN) induced in male Wistar albino rats |
200mg/kg for 14 weeks. |
↓ B.wt, O. wt, Liver weight ↓ 8-OHdG, TBARS ↑SOD, CAT, GPx, GR and GSH levels ↓ALT, AST, ALP, TC, TGs levels ↓GGT and LDH levels |
[25] |
|
CCl4 induced in male Wistar rats |
1 mL/kg for 4h |
↓LDH, ALP, TB, AST levels ↓TP, TC and TGs levels ↓MDA,ROS levels ↓ Oxidative stress ↓GSH, SOD ↓NF-κB, TNF-α, IL-6, IL-8, IL-10, iNOS |
[26] |
|
STZ induced male Wister rats and hypertensive rats |
600 mg/kg/day for 28 days |
↓TGs, SGOT, cholesterol, pancreatic islet damage levels ↑ B.wt and metabolic functions ↓ Blood glucose, MABP, ↑ Pancreas and β-cell protection |
[27] |
|
STZ-induced male Sprague Dawley rats |
250 and 500 mg/kg body weight for 4 weeks |
↓ Lipid profile- TGs, TC, LDL levels and increased HDL levels ↓ fasting blood glucose levels Improvement of glycolysis and gluconeogenesis, TCA cycle, ketone body synthesis and hypotaurine metabolism
|
[28] |
|
STZ induced in male Wistar rats |
200 and 400 mg/kg body weight for 28 days |
Prevention of weight loss ↓ Lipid profile- TGs, TC, LDL levels and increased HDL levels ↓ Liver function markers- ALP, AST, ALT levels ↓ Serum urea and creatinine levels ↓ MDA level ↑ Antioxidant enzymes, including SOD, CAT, GSH |
[29] |
4. Role of Phyllanthus niruri in Diabetes
Table 2: Effects of Phyllanthus niruri on Diabetes in preclinical studies
|
Dose & Duration |
Result/Findings |
Ref. |
|
|
CCl4-induced male Wistar rats |
25,50,100, and 200 mg/kg |
↓ALT, ALP, TB, and AST levels in a dose-dependent manner. ↓TC, TG. No change in Glucose level. ↓Urea and creatinine. ↑GSH, ↓ ROS, MDA. ↓NF-kB, IL-6, IL-8, IL-10, TNF ↑SOD, CAT, GSP, and GR. ↓Ballooning degeneration, fatty changes, necrosis, and infiltration of inflammatory cells infiltration, and marked congestion in a dose-dependent manner. |
[26] |
|
CCl4-induced albino Wistar rats
|
50mg/kg,100mg/kg, and 50 and 100mg/kg for 5 days. |
↓SGPT, SGOT, SALP, total bilirubin, direct bilirubin, ↓TC, total proteins, and LPO. ↑CAT and SOD. ↑Repair of hepatic tissue damage |
[65] |
|
HFD-induced male albino rats |
250mg/kg for 105 days |
↓ALT, AST, ALP ↓TC, TG, VLDL-c, LDL-C, HDL-c ↓glucose, insulin, and HOMA-IR. no change in serum bilirubin, HOMA-β level. ↑Albumin & A/G ratio, TP, Globulin. C3 levels |
[66] |
|
CCL4, along with 40% alcohol, induced male and female Sprague- Dawley rats |
Phyllanthus niruri combined with Tephrosia purpurea, Boerhavia diffusa, and Andrographis paniculata 250 and 500 mg/kg b.w. for 21 days |
↓ALT, ALP, Serum bilirubin, AST TP remained similar ↑B.W. loss
|
[67] |
|
Isoniazid and Rifampicin induced Sprague Dawley rats |
P.niruri combined with A. paniculata 125mg/kg, PO for 14 days. |
↓Total bilirubin, SGOT. ↓SOD, Catalase enzymes. No signs of necrosis. |
[68] |
|
HFD-induced diabetic mellitus male Rattus norvegicus rats |
capsule combination of Channa striata, P.niruri, and Curcuma xantorrhiza |
Improved liver functions |
[69] |
|
Imidacloprid-induced chicken embryos |
200µl extract of |
↓AST, ALT, ALP. ↓Creatinine, BUN. ↓Amylase. ↓Cholesterol, TG, Protein, Albumin. ↓Necrosis, DBS, BD, CVR. |
[70] |
|
CCl4-induced male albino rats |
P. niruri combined with Plantago major (500 mg/kg/day) for 31 days. |
↓TNF-α, IL-1β, and IL18 ↓MDA with ↑ SOD, GSH level |
[71] |
|
Artificial sweeteners, aspartame-induced female Swiss albino Mus musculus |
100mg/kg for 30 and 60 days |
↓ALP, ALT, AST, GGT, LDH, bilirubin, hepatic TP. ↓renal ALP, renal AST, renal ALT, renal creatinine. ↓glucose, cholesterol, triglyceride. ↓necrosis, inflammatory cells. |
[72] |
|
HFD-induced male Sprague-Dawley rats |
1000 mg/kg for 8 weeks |
improved liver histology, ↓adiponectin, RBP4, TNFα, IL-6, progranulin,and vaspin. no signs of inflammation, steatosis, or fibrosis. ↓PPARℽ, SLC10A2, and Collα1. |
[73] |
|
CCl4 with coconut oil induced female Swiss albino mice |
200mg/kg for 2 weeks |
↓AST, ALT, ALP, hepatic lipid profile. ↓Serum total protein, lipid peroxidation. ↓Necrosis, inflammatory cells.
|
[74] |
|
D-Galn induced male Wistar rats |
800mg/kg for 21 days |
↓AST, ALT, bilirubin. ↓creatinine, urea. ↓necrosis, inflammation cells. |
[75] |
|
CCl4 with diluted olive oil induced male Swiss albino mice |
100mg/kg for 20 days |
↓AST, ALT, ALP, bilirubin, liver weight. ↓TP, Albumin, Globulin, cholesterol. ↓glucose ↑RBC,PCV, HB, Platelet. TWBC. ↓Fatty change, necrosis, and lymphocyte infiltration. |
[76] |
|
Paracetamol induced Wistar rats |
200mg/kg for 7 days |
↓AST, ALP, ALT, bilirubin. ↑TP ↑GSH, LPO, Catalase. ↓necrosis, inflammatory cells. |
[77] |
|
Aflatoxin-induced Wistar albino rats |
300mg/kg P. niruri for 40 days
|
↓SGOT, SGPT, ALP, bilirubin. ↑Protein. ↑RBC, Hb, PVC, MCV, MCH, MCHC, lymphocyte, platelet, WBC, neutrophils. |
[78] |
5. Role of Phyllanthus niruri in Chronic Kidney Disease
Table 3: Renoprotective effects of Phyllanthus niruri in preclinical studies
|
Experimental Model |
Dose & Duration |
Result/ Findings |
Ref. |
|
Ca-ox induced Male C57BL/6 mice
|
80 mg/kg once daily for 7 days |
↓ Kidney calcium content, Serum creatinine level ↓MDA level with ↑ GPx activity, Ca-Ox deposition level ↓ SQLE, HMGCS1, SCD gene expression ↓ p53 expression ↓ Tubulointerstitial injury, crystal deposition and inflammation |
[50] |
|
NaCl induced female Wistar rat
|
2% NaCl in drinking water for 4 weeks |
↑ ECM ↓ Fibrosis |
[51] |
|
STZ-NA induced male diabetic Wistar rats |
- 200, 400 mg/kg for 28 days |
↓ serum creatinine, urine creatinine, urine output (mL), serum urea, BUN, serum uric acid, urine protein, Na+, k+ level in a dose dependent manner ↑ Ccr activity ↓ SOD, CAT and GPx activity ↑NF-kβ, Ikkβ, TNF-α and ILs (IL-1β and IL-6) gene expression ↓ Fibrosis and apoptosis |
[52] |
|
CaOx seed induced adult male Wistar rats
|
administered orally at 1.25 mg/mL/day for 42 days. |
↑ creatinine level ↑ Na+, K+, ↓ uric acid, Oxalate and no change in Ca2+ in Urinary analysis ↓ Na+, Oxalate, ↑ K+, Mg2+, Ca2+, Uric Acid in Plasma analysis ↓ Calculus weight ↑ GAG content |
[53] |
|
Paracetamol induced Rat
|
- 50,100,200 mg/kg for 8 days |
↓ MDA level in a dose dependent manner |
[54] |
|
D-Galactosamine-induced male Wistar rat
|
- 100, 800 mg/kg for 21 days |
↓ Bilirubin, creatinine level in a dose dependent manner ↓ AST, ALT activities level in a dose dependent manner
|
[55] |
|
Alloxan-induced male wister rats
|
- 1.35, 2.7, 5.4 mg/kg for 4 weeks |
↓ Blood glucose level in dose dependent manner ↓ Creatinine and BUN level in a dose dependent manner ↓ AST, ALT activities level in a dose dependent manner
|
[56] |
6. Role of Phyllanthus niruri in Hepatic fibrosis
Serological evidence of anti-nuclear antibody (ANA), with or without anti-smooth muscle antibody (SMA), is linked to it. Conversely, children and adolescents are primarily affected by Type 2 AIH. Anti-liver kidney microsomal type 1 (anti-LKM1) antibody, with or without anti-liver cytosol type 1 (anti-LC1) antibody, is associated with 75% of AIH cases, regardless of subtype [64]. T-helper cell-mediated recognition of liver autoantigens and B-cell generation of autoantibodies initiate the self-attack of AIH, which is sustained by a decrease in the quantity and activity of regulatory T-cells. In addition to a genetic predisposition, environmental factors and infections have been investigated as triggers for various disorders [64].
Ezzat et al. conducted standard liver function tests (LFTs): ALT, ALP, TB, and AST in the CCl4-induced male Wistar rat model with Phyllanthus niruri [26]. In a dose-dependent manner, Phyllanthus niruri treatment at 25, 50, 100, and 200 mg/kg body weight decreases ALT, ALP, TB, and AST levels, and reduces TC, TG, Urea, and creatinine levels, but does not change glucose levels [26].
The inflammatory markers, such as NF-KB, IL-6, IL-8, IL-10, and TNF, decreased, respectively, and, compared to the CCL4 rats, Phyllanthus niruri treatment neutralized the effects of the antioxidant enzymes SOD, CAT, GSP, and GR by increasing their levels [26]. The histopathological study showed a reduction in ballooning degeneration, fatty changes, necrosis, and inflammatory cell infiltration, with marked congestion [26]. Kodoli et al. reported that doses of 50 and 100mg/kg of Phyllanthus niruri for 5 days, respectively, reduce the levels of SGPT, SGOT, SLAP, total bilirubin, direct bilirubin, total cholesterol, and proteins, and increase the levels of CAT and SOD [65]. The histopathology study shows that both treated groups (50 and 100mg/kg Phyllanthus niruri) reduce hepatic tissue damage, with no focal hemorrhage and only slight ballooning of hepatocytes on H&E staining [65]. Hashem et al. state that the extract of 250mg/kg doses Phyllanthus niruri decreased the rate of liver enzyme markers (ALT, AST, ALP) in the selected rats, significantly reduced the level of total cholesterol (TC), Triglycerides (TG), VLDL, LDL, and HDL when applied for 105 days on a high-fat diet (HFD) induced male albino rats [66]. Although Phyllanthus niruri reduced the levels of the diabetes markers (glucose, insulin, and HOMA-IR), no change in serum bilirubin or HOMA-β level was observed. It also increased albumin levels, the A/G ratio, total protein (TP), globulin, and C3 [66]. Dey et al. also reported on the hepatoprotective activity of Phyllanthus niruri [67]. Treatment with Phyllanthus niruri in CCl4, along with 40% alcohol, in male and female Sprague- Dawley rats showed a decrease in liver enzyme biomarkers, and some selected rats showed an improvement in total body weight. In this study, Phyllanthus niruri was combined with Tephrosia purpurea, Boerhavia diffusa, and Andrographis paniculata, at doses of 250 and 500 mg/kg for 21 days [67]. The study by Khanth et al. found that 125mg/kg Phyllanthus niruri, in combination with A. paniculata, administered for 14 days to isoniazid-rifampicin-induced Sprague Dawley rats, decreased the levels of total bilirubin, SGOT, SOD, and catalase [68]. There was no evidence of necrosis during staining, unlike in the disease-induced group [68]. Simarmata et al. found that a combination of Snakehead Fish Extract (Channa striata), Meniran (Phyllanthus niruri L.), and Temulawak (Curcuma xanthorrhiza) improved liver function in HFD-induced diabetes in male Rattus norvegicus rats [69]. Histopathology revealed administration of combined capsule improved liver structure and decreased fat accumulation [69]. Khandia et al. reported that Phyllanthus niruri (200µl) significantly decreases the levels of liver enzyme markers (AST, ALT, ALP); kidney functional biomarkers (creatinine, BUN); amylase; and lipid biomarkers (cholesterol, triglyceride, protein, albumin) when applied to Imidacloprid-induced chicken embryos for 17 days [70]. Besides, Hematoxylin and eosin (H&E) staining in the histological investigations revealed that in sections of the chicken embryo liver, there were signs of reduced necrosis, normal sinusoids, dilated blood sinusoids (DBS), bile ducts (BD), and CVR (central vein with RBCs) [70].
Naik et al. showed that aspartame-induced female Swiss albino mice, Mus musculus, received 100 mg/kg of Phyllanthus niruri for 30 and 60 days, respectively, and that following treatment was available to reduce liver enzyme markers (ALT, ALP, AST, GGT, LDH), bilirubin, and hepatic total protein, relative hepatic weight; renal enzyme markers (ALP, AST, ALT, and creatinine); relative renal weight; glucose, cholesterol, and triglycerides [71]. Additionally, their histopathological investigations showed that lobular structure returned to normal, the polyhedral arrangement of hepatocytes around the central vein was normal, hepatic cells enclosed the hepatic sinusoids, and inflammation was reduced [71,72]. Al Zarzour et al. reported that a 1000 mg/kg dose of Phyllanthus niruri administered for eight weeks to male Sprague Dawley rats fed a high-fat diet significantly decreased the levels of AST, ALT, ALP, and AST/ALT, obesity-related metabolic dysfunction, insulin resistance biomarkers (Adiponectin, RBP4, Progranulin, and Vaspin), as well as the weight of the liver and visceral fat [73]. Serum TNFα, IL-6, PPARℽ, SLC10A2, CFD, PNPLA2, and COL1α1 levels were lower than those of the only high-fat diet group. Hematoxylin and eosin (H&E) staining in the histological investigations revealed no evidence of fibrosis, steatosis, or inflammation. The hepatoprotective properties of Phyllanthus Niruri are confirmed by the entire investigation [73]. According to Balakrishnan et al., 200 mg/kg of Phyllanthus niruri for two weeks decreased serum enzyme markers (AST, ALT, ALP), reduced the hepatic lipid profile, increased serum protein, and increased hepatic TBARS concentration, and inhibited hepatic lipid peroxidation in CCl4- and coconut oil-induced female Swiss albino mice [74]. These findings suggest that Phyllanthus niruri may have hepatoprotective effects. Hematoxylin and eosin staining was used for histomorphological investigation, which revealed no fatty arrangement of hepatic cells and no necrosis; the cells had distinct cytoplasm, nuclei, and prominent central veins [74]. Shanmugam et al. used 800 mg/kg body weight of Phyllanthus niruri to treat male Wistar rats that had been intraperitoneally given D-galactosamine [75]. AST, ALT, bilirubin, and creatinine levels all dropped after Phyllanthus niruri treatment. Conversely, the urea level was considerably higher. The histological investigations revealed signs of regeneration of the sinusoids, hepatocytes, and central veins [75].
According to Manonmani et al., 100 mg/kg of Phyllanthus niruri for 20 days reduced blood levels of liver enzymes (AST, ALT, and ALP) in male Swiss albino mice treated with CCl4 in diluted olive oil, suggesting it can protect liver function [76]. Additionally, it lowers glucose, albumin, globulin, total protein, and cholesterol. However, the Total White Blood Cell Count (TWBC) decreased, while the hematological parameters (RBC, PCV, HB, and platelets) increased [76]. Hematoxylin and Eosin staining was used for the histopathology investigations, which revealed decreased necrosis, fewer inflammatory cells, and hepatic cell regeneration [76]. Novianta et al. found that when Wistar rats were given 200 mg/kg b.w. of Phyllanthus niruri for 7 days after paracetamol treatment, AST, ALP, ALT, and bilirubin levels decreased, while total protein (TP), GSH, LPO, and catalase levels increased [77]. Additionally, the histological analysis revealed reduced hepatic membrane damage, inflammatory cell infiltration, and necrosis. [77]. Ramamurthy et al. showed that administering 300 mg/kg of Phyllanthus niruri to aflatoxin-induced Wistar albino rats for 40 days decreased serum levels of liver enzymes (SGOT, SGPT, ALP, & bilirubin) while increasing total protein, platelets, WBC, and neutrophils [78]. The therapeutic effects of the plant extract were confirmed, as it reversed aflatoxin-induced anemia and immunosuppression by restoring depleted levels of RBC, Hb, PCV, and lymphocytes toward normal ranges [78].
Table 4: Hepatoprotective effects of Phyllanthus niruri in preclinical studies
|
Dose & Duration |
Result/Findings |
Ref. |
|
|
CCl4-induced male Wistar rats |
25,50,100, and 200 mg/kg |
ALT, ALP, TB, and AST levels in a dose-dependent manner. TC, TG. No change in Glucose level. urea, and creatinine. GSH, ROS, MDA. NF-kB, IL-6, IL-8, IL-10, TNF SOD, CAT, GSP, and GR. Ballooning degeneration, fatty changes, necrosis, and infiltration of inflammatory cells infiltration, and marked congestion in a dose-dependent manner. |
[26] |
|
CCl4-induced albino Wistar rats
|
50mg/kg,100mg/kg, and 50 and 100mg/kg for 5 days. |
SGPT, SGOT, SALP, total bilirubin, direct bilirubin, TC, total proteins, and LPO. CAT and SOD. Repair of hepatic tissue damage |
[65] |
|
HFD-induced male albino rats |
250mg/kg for 105 days |
ALT, AST, ALP TC, TG, VLDL-c, LDL-C, HDL-c glucose, insulin, and HOMA-IR. no change in serum bilirubin, HOMA-β level. Albumin & A/G ratio, TP, Globulin. C3 levels |
[66] |
|
CCL4, along with 40% alcohol, induced male and female Sprague- Dawley rats |
Phyllanthus niruri combined with Tephrosia purpurea, Boerhavia diffusa, and Andrographis paniculata 250 and 500 mg/kg b.w. for 21 days |
ALT, ALP, Serum bilirubin, AST TP remained similar B.W. loss
|
[67] |
|
Isoniazid and Rifampicin induced Sprague Dawley rats |
P.niruri combined with A. paniculata 125mg/kg, PO for 14 days. |
Total bilirubin, SGOT. SOD, Catalase enzymes. No signs of necrosis. |
[68] |
|
HFD-induced diabetic mellitus male Rattus norvegicus rats |
capsule combination of Channa striata, P.niruri, and Curcuma xantorrhiza |
Improved liver functions |
[69] |
|
Imidacloprid-induced chicken embryos |
200µl extract of |
AST, ALT, ALP. Creatinine, BUN. Amylase. Cholesterol, TG, Protein, Albumin. Necrosis, DBS, BD, CVR. |
[70] |
|
CCl4-induced male albino rats |
P. niruri combined with Plantago major (500 mg/kg/day) for 31 days. |
TNF-α, IL-1β, and IL18 MDA with SOD, GSH level |
[71] |
|
Artificial sweeteners, aspartame-induced female Swiss albino Mus musculus |
100mg/kg for 30 and 60 days |
ALP, ALT, AST, GGT, LDH, bilirubin, hepatic TP. renal ALP, renal AST, renal ALT, renal creatinine. glucose, cholesterol, triglyceride. nercosis, inflammatory cells. |
[72] |
|
HFD-induced male Sprague-Dawley rats |
1000 mg/kg for 8 weeks |
liver histology, adiponectin, RBP4, TNFα, IL-6, progranulin,and vaspin. no signs of inflammation, steatosis, or fibrosis. PPARℽ, SLC10A2, and Collα1. |
[73] |
|
CCl4 with coconut oil induced female Swiss albino mice |
200mg/kg for 2 weeks |
AST, ALT, ALP, hepatic lipid profile. Serum total protein, lipid peroxidation. nercosis, inflammatory cells.
|
[74] |
|
D-Galn induced male Wistar rats |
800mg/kg for 21 days |
AST, ALT, bilirubin. creatinine, urea. necrosis, inflammation cells. |
[75] |
|
CCl4 with diluted olive oil induced male Swiss albino mice |
100mg/kg for 20 days |
AST, ALT, ALP, bilirubin, liver weight. TP, Albumin, Globulin, cholesterol. glucose RBC,P CV, HB, Platelet. TWBC. fatty change, necrosis, and lymphocyte infiltration. |
[76] |
|
Paracetamol induced Wistar rats |
200mg/kg for 7 days |
AST, ALP, ALT, bilirubin. TP GSH, LPO, Catalase. necrosis, inflammatory cells. |
[77] |
|
Aflatoxin-induced Wistar albino rats |
300mg/kg P. niruri for 40 days
|
SGOT, SGPT, ALP, bilirubin. Protein. RBC, Hb, PVC, MCV, MCH, MCHC, lymphocyte, platelet, WBC, neutrophils. |
[78] |
7. Role of Phyllanthus niruri on Inflammation
The immune system's basic biological reaction to damaging stimuli, including infection, tissue damage, poisons, or autoimmune responses, is inflammation. Its main goals are to remove damaged tissue, initiate the healing process, and eliminate the original cause of cell damage [79]. Blood vessels, immune cells, and chemical mediators such as chemokines and cytokines work together to cause inflammation. Even though inflammation has a protective function, imbalance of this process can lead to the onset of illness [79]. According to epidemiological statistics, indicators such as high-sensitivity C-reactive protein (hs-CRP) indicate that a significant proportion of people have increased systemic inflammation. A total of 12,946 unweighted individuals, or 315,354,183 adults in the United States, were evaluated. 34.63% of people suffer from systemic inflammation [80]. 15.1%, 29.1%, and 41.8% of those 20 years of age and older had no disease, undiagnosed disease, and diagnosed disease with inflammation, respectively. Non-Hispanic Black persons had the highest prevalence (50.35%) among those with a diagnosis of increased inflammation when stratified by race/ethnicity, followed by Hispanics (46.13%) and Non-Hispanic Whites (40.15%) [80]. Causes of inflammation can be both external and internal, according to original epidemiological research, the main causes of high systemic inflammatory markers are age, obesity, smoking, poor food, and sedentary lifestyle. Chronic low-grade inflammation is facilitated by the active secretion of pro-inflammatory cytokines including TNF-α and IL-6 by adipose tissue, particularly visceral fat [81].The acute inflammatory model of carrageenan-induced inflammation is typified by a biphasic reaction. The release of bradykinin, serotonin, and histamine mediates the early phase (0–2 h), leading to increased vascular permeability and edema development [82].
Prostaglandins, nitric oxide, and pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) via COX-2 and NF-κB activation are the key drivers of the late phase (3–6 h). Oxidative stress and neutrophil infiltration worsen tissue damage and prolong inflammation [82]. By attaching itself to Toll-like receptor-4 (TLR4) on immune cells including macrophages and monocytes, lipopolysaccharide (LPS) causes inflammation. Pro-inflammatory mediators (TNF-α, IL-1β, IL-6, COX-2, and iNOS) are released after downstream MyD88- and TRIF-dependent signaling pathways are activated, causing NF-κB and IRFs to translocate into the nucleus. Endothelial dysfunction, tissue damage, and systemic inflammatory reactions are brought on by an overabundance of cytokines and reactive oxygen/nitrogen species [83]. When LPS binds to TLR4 on macrophages, the MyD88/NF-κB signaling cascade is activated, increasing the production of pro-inflammatory mediators such as CCL2, IL-1β, TNF-α, and IL-6 and encouraging inflammatory responses and death in alveolar macrophages [84]. In acute lung injury, the TLR4/MyD88/NF-κB axis stimulates the production of cytokines and chemokines that increase the recruitment of inflammatory cells and tissue damage. Circ-Phkb downregulation attenuates inflammation in LPS-induced macrophages via lowering CCL2 production and NF-κB activation [84].
According to Sutrisna et al., the administration of Phyllanthus niruri at doses of 250, 500, and 1000 mg/kg body weight significantly reduced paw edema volume in a dose-dependent manner in a carrageenan-induced Swiss albino rat model, suggesting a strong anti-inflammatory effect compared with the carrageenan control group [85]. The anti-inflammatory potential of the natural compound was further confirmed in another experiment by Ronia Mostofa et al., using a carrageenan-induced model in female Swiss albino rats. Treatment at doses of 100, 200, and 400 mg/kg body weight resulted in a significant, dose-dependent decrease in edema volume [86]. In Swiss Webster rats induced with 1 mL of 1% acetic acid, Dian Arsanti Palupi et al. showed that a combination of dry extracts of Phyllanthus niruri (Meniran) and Moringa oleifera leaves exhibited significant analgesic activity, as evidenced by a decreased pain response compared to the control group [87]. Hossain et al. demonstrated that administering the extract at a concentration of 400 mg/kg for 4 hours significantly decreased edema volume in male and female Swiss albino rats produced with carrageenan, indicating an efficient acute anti-inflammatory response in both genders [88]. According to Jeje et al., treatment with 20 mg/kg of Phyllanthus niruri for two days significantly reduced IFN-γ concentrations in blood serum, decreased albumin denaturation, and suppressed enzyme release in an LPS-induced inflammatory model using female C57BL/6 mice, indicating potent anti-inflammatory and immunomodulatory effects compared to the LPS-treated control group [89].
Table-5 Effects of Phyllanthus niruri on inflammation in preclinical studies
|
Dose & Duration |
Result/ Findings |
Ref. |
|
|
Carrageenan-induced Swiss albino rats
|
250, 500, 1000 mg/kg |
↓ Edema volume in a dose dependent manner |
[85] |
|
Carrageenan-induced female Swiss albino rats |
100, 200, 400 mg/kg |
↓ Edema volume in a dose dependent manner |
[86] |
|
Combination of dry extracts of meniran leaves (Phyllanthus niruri) and moringa leaves (Moringa oleifera) induced Swiss Webster rats |
1 mL of 1% acetic acid |
↓ Analgesic activity |
[87] |
|
Carrageenan-induced male and female Swiss albino rats |
400mg/kg for 4 hours |
↓ Edema volume |
[88] |
|
LPS-induced female C57BL/6 mice
|
20 mg/kg for 2 days |
↓ IFN-γ concentrations in the blood serum ↓ Albumin denaturation ↓ Enzyme release |
[89] |
8. Clinical Studies on the Effect of Phyllanthus niruri in Metabolic Syndrome
Sowjanya et al. reported that in a block-randomized, double-blind, parallel-arm, placebo-controlled trial with 454 patients, including 100 patients with alcoholic hepatitis, P. niruri treatment for 4 weeks significantly reduced AST, ALT, ALP, GGTP, and bilirubin levels, with an increase in albumin levels. TC and TG levels also decreased as total antioxidant activity increased. Phyllanthus niruri also improved renal parameters by reducing creatinine and uric acid levels [90]. Hassan MRA et al. reported that in a 12-month, randomized, double-blind, placebo-controlled study involving 267 patients, 112 received Phyllanthus niruri and 114 received a placebo. The treatment decreased liver biomarker levels (AST, ALP, GGT, ALT) with no change in the AST/ALT ratio & CAP score. Besides, it also reduced the fibrosis score, with no change in HDL & slightly decreased levels of LDL and Total Cholesterol (TC) [91].
Shaker et al. reported that, in a randomized, double-blind, placebo-controlled, three-arm, interventional trial, 146 patients with non-alcoholic steatohepatitis were treated with P. niruri for 36 weeks, and the treatment significantly reduced ALT and AST levels, CAP score & FAST score [92]. Besides, there was no change in KPa and FIB-4 score. Phyllanthus niruri treatment also lowered lipid profile biomarkers (HDL, LDL, TG) levels [92]. Khan MN et al. reported an open-label, randomized controlled trial in which 68 adult patients with alcoholic liver disease received Phyllanthus niruri treatment for 12 weeks, and after treatment, levels of liver biomarkers (total bilirubin, direct bilirubin, SGOT, SGPT, ALP, GGT, and MELD score) decreased significantly. His study reported reduced serum albumin and globulin levels after treatment [93]. Kumar et al. reported a 12-week, double-blind, randomized, active-controlled, multicenter, prospective trial in which 132 adult patients with liver disease received a P. niruri tablet, and ALT, AST, ALP, TB, and direct & indirect bilirubin levels were dramatically reduced [94]. All the other liver function tests: total proteins, albumin, AG ratio, and PT/INR ratio remained within the normal range, with their levels lowered [94]. Shaker et al. reported a phase II, multicenter, randomized, double-blind, placebo-controlled, and three-arm interventional clinical trial that was conducted in patients for 36 weeks with apparent risk factors for non-alcoholic steatohepatitis (NASH) [95]. The product, Heptex, consists of Phyllanthus niruri and Silybum marianum. Phyllanthus niruri tablet capsule 200mg and Silybum marianum capsule 100 mg. P. niruri capsule was in a higher dose, and Silybum marianum was in a lower dose [95]. Then, ALT and AST decreased in both the low- and high-dose groups. TC showed a significant change in the low-dose group, whereas HDL, LDL, and TG did not change. The CAP score decreased, and there was no significant change in the Fib-4 score or liver stiffness with a lower FAST score [95].
Sowjanya et al. mentioned a Phase II clinical trial, a block-randomized, double-blind, parallel-arm, placebo-controlled study, conducted in patients with mild to moderate alcoholic hepatitis. After Phyllanthus niruri treatment, total antioxidant levels and appetite increased significantly [96]. There were no significant changes in AST, ALP (liver enzymes), GGT, bilirubin, albumin, INR, urea and creatinine, TG, TC, and oxidant levels [96]. Hassan et al. conducted a randomized controlled, double-blind, placebo-controlled, parallel-group trial in patients with mild to moderate non-alcoholic fatty liver disease (NAFLD) [97]. The treatment was 250mg of Phyllanthus niruri for 12 months. The treatment showed a significant reduction in the fibrosis score and improvements in AST, ALT, AST/ALT ratio, and CAP score. The treatment was well-tolerated and showed a potential antifibrotic effect. Moreover, less effect on steatosis and metabolic markers [97].
Table-6 Effects of Phyllanthus niruri in clinical studies|
Study type |
Dose& Duration |
Results |
Ref. |
|
Block randomized, double-blind, parallel-arm placebo-controlled trial (100 alcoholic patients) |
500 mg tablet twice daily for 4 weeks |
AST, ALT, ALP, GGTP, Bilirubin Albumin, creatinine, Urea. TC, TG. INR total oxidant, total antioxidant. |
[90] |
|
Randomized, double-blind, placebo-controlled trial (112 non- alcoholic patients) |
Hepar-P capsule (250mg) twice for 12 months |
ALP, GGT; AST, ALT, CAP score, AST/ALT: no change Fibrosis, HDL: no change, LDL, TC.
|
[91] |
|
Randomized, double-blind, placebo-controlled, three-arm, interventional trial (146 non-alcoholic steatohepatitis patients) |
HeptexR capsules (200 mg) three times for 36 weeks |
ALT, AST. CAP, FAST. KPa, FIB-4: no change. HDL, LDL, TG. |
[92] |
|
Open-label, randomized controlled trial (68 adult ALD patients) |
BoozLivTM syrup twice daily for 12 weeks. |
TB, DB, SGPT, SGOT, ALP, GGT, MELD score. serum albumin, serum globulin. |
[93] |
|
Double- blind, randomized, active- controlled, multicenter, prospective (132 adult liver disease patients) |
Hepano tablet for 12 weeks |
AST, ALT, ALP, TB, Direct & indirect bilirubin. TP, albumin, AG ratio, PT/INR ratio.
|
[94] |
|
PhaseII, Multicenter, Randomized, Double-blind, Placebo-controlled,Three-arm interventional clinical trial.Conducted in patients with apparent risk factors for non-alcoholic steatohepatitis (NASH) |
PN capsule 200mg and SM capsule 100 mg for 36 weeks |
↓ ALT , AST decreased in low and high dose group TC significant change in low dose group HDL,LDL, TG no changes ↓ CAP score No significant change in Fib-4 score and liver stiffness ↓ FAST score |
[95] |
|
Phase II clinical trial, Block-randomized, Double-blind, Parallel-arm, Placebo-controlled, Conducted in patients with mild to moderate alcoholic hepatitis |
500mg capsule twice daily for 4 weeks |
Total antioxidant levels and appetite increased significantly No significant change in AST, ALP (liver enzymes), ALP,GGT, Bilirubin, albumin, INR, Urea and creatinine, TG, TC, and oxidant levels |
[96] |
|
Randomized controlled trial, Double-blind, Placebo-controlled, Parallel-group, Duration: 12 months (1 year), conducted in patients with mild to moderate non-alcoholic fatty liver disease (NAFLD) |
250mg PN for 12 months |
Significantly reduced fibrosis score Improvement in AST, ALT, AST/ALT ratio and CAP score Well tolerated and potential antifibrotic effect Less effect for steatosis and metabolic markers |
[97] |
9. Toxicological Perspectives for Phyllanthus niruri treatment
Despite the promising pharmacological activities of Phyllanthus niruri, its long-term safety and toxicological profile require further systematic investigation before its widespread therapeutic application. Although traditional use and available clinical studies suggest reasonable tolerability, the safety evidence remains insufficient to establish a definitive therapeutic window, particularly for prolonged administration and higher doses. Variations in extraction methods, phytochemical composition, dosage, and treatment duration may influence its biological activity and potential toxicity.
Furthermore, the possibility of herb-drug interactions warrants careful consideration, especially in patients with obesity-related comorbidities who frequently receive antidiabetic, antihypertensive, and lipid-lowering medications. Comprehensive toxicological evaluations, including acute, subacute, and chronic toxicity studies, genotoxicity, reproductive toxicity, and organ-specific safety assessments, are necessary to identify potential adverse effects and establish safe exposure limits. Particular attention should be paid to hepatic, renal, hematological, and metabolic parameters, as well as histopathological examination of vital organs. Establishing standardized extracts with well-characterized phytochemical profiles and conducting systematic pharmacovigilance studies will be essential to ensure product consistency, minimize potential risks, and support the safe translation of P. niruri into clinical practice.
10. Future Directions of Research for Phyllanthus niruri Treatment
11. Conclusion
There is a growing body of scientific evidence supporting the therapeutic potential of Phyllanthus niruri. All these results from the cited reviews show that P. niruri exhibits a wide range of pharmacological activities, including anti-obesity, hypolipidemic, antidiabetic, hepatoprotective, nephroprotective, antioxidant, and anti-inflammatory effects. Experimental studies have shown that P. niruri can improve lipid metabolism, reduce body weight gain, enhance glucose homeostasis, suppress inflammatory mediators, and protect hepatic and renal tissues from pathological damage. These beneficial effects are mediated through the modulation of multiple molecular pathways involved in inflammation, oxidative stress, fibrosis, and metabolism.
Author Contribution
Funding
Institutional Review Board Statement
Acknowledgments
Conflicts of Interest
Data Availability Statement
References
1. Mao, X.; Wu, L.F.; Guo, H.L.; Chen, W.J.; Cui, Y.P.; Qi, Q.; Li, S.; Liang, W.Y.; Yang, G.H.; Shao, Y.Y.; Zhu, D.; She, G.M.; You, Y.; Zhang, L.Z. The Genus Phyllanthus: An Ethnopharmacological, Phytochemical, and Pharmacological Review. Evid. Based Complement. Alternat. Med. 2016, 2016, 7584952. https://doi.org/10.1155/2016/7584952
2. Kaur, N.; Kaur, B.; Sirhindi, G. Phytochemistry and Pharmacology of Phyllanthus niruri L.: A Review. Phytother. Res. 2017, 31(7), 980–1004. https://doi.org/10.1002/ptr.5825
3. Olawale, J.T.; Bando, H.; Fukuda, Y.; Oluwafemi, I.E.; Kato, K. Aqueous Extract of Phyllanthus niruri Protects Against Severe Malaria by Blocking Erythrocyte Invasion and Modulating the Host Immune Response. bioRxiv 2021, 2021.07.09.451735. https://doi.org/10.1101/2021.07.09.451735
4. Shahrul. Phyllanthus niruri. 2021 [cited 2021 March 6].
5. Ghosh, A.B.M.; Banerjee, A.; Chattopadhyay, S. An Insight into the Potent Medicinal Plant Phyllanthus amarus Schum. and Thonn. Nucleus 2022, 65(3), 437–472. https://doi.org/10.1007/s13237-022-00409-z
6. Khandia, R.; Pathe, C.S.; Vishwakarma, P.; Dhama, K.; Munjal, A. Evaluation of the Ameliorative Effects of Phyllanthus niruri on the Deleterious Insecticide Imidacloprid in the Vital Organs of Chicken Embryos. J. Ayurveda Integr. Med. 2020, 11, 495–501. https://doi.org/10.1016/j.jaim.2019.03.003
7. Obidike, I.C.; Ndukuba, M.; Salawu, O.A. The Anti-Inflammatory and Antinociceptive Properties of the Chloroform Fraction from Phyllanthus niruri Plant Is Mediated via the Peripheral Nervous System. J. Diet. Suppl. 2010, 7(4), 341–350. https://doi.org/10.3109/19390211.2010.522553
8. Afshin, A.; Forouzanfar, M.H.; Reitsma, M.B.; Sur, P.; Estep, K.; Lee, A.; Marczak, L.; Mokdad, A.H.; Naghavi, M.; Salama, J.S.; et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N. Engl. J. Med. 2017, 377(1), 13–27. https://doi.org/10.1056/NEJMoa1614362
9. Brook, R.D.; Rubenfire, M.; Vodnala, D. Secondary Causes of Dyslipidemia. Am. J. Cardiol. 2012, 110(6), 823–825. https://doi.org/10.1016/j.amjcard.2012.04.062
10. Ahmed, S.K.; Mohammed, R.A. Obesity: Prevalence, Causes, Consequences, Management, Preventive Strategies and Future Research Directions. Metabol. Open 2025, 27, 100375. https://doi.org/10.1016/j.metop.2025.100375
11. Cho, S.M.J.; Lee, H.J.; Shim, J.S.; Song, B.M.; Kim, H.C. Associations between Age and Dyslipidemia Are Differed by Education Level: The Cardiovascular and Metabolic Diseases Etiology Research Center (CMERC) Cohort. Lipids Health Dis. 2020, 19(1), 12. https://doi.org/10.1186/s12944-020-1189-y
12. Loid, P.; Mustila, T.; Mäkitie, R.E.; Viljakainen, H.; Kämpe, A.; Tossavainen, P.; Lipsanen-Nyman, M.; Pekkinen, M.; Mäkitie, O. Rare Variants in Genes Linked to Appetite Control and Hypothalamic Development in Early-Onset Severe Obesity. Front. Endocrinol. 2020, 11, 81. https://doi.org/10.3389/fendo.2020.00081
13. Martins, M.C.; Trujillo, J.; Freitas-Vilela, A.A.; Farias, D.R.; Rosado, E.L.; Struchiner, C.J.; Kac, G. Associations between Obesity Candidate Gene Polymorphisms (Fat Mass and Obesity-Associated (FTO), Melanocortin-4 Receptor (MC4R), Leptin (LEP) and Leptin Receptor (LEPR)) and Dietary Intake in Pregnant Women. Br. J. Nutr. 2018, 120(4), 454–463. https://doi.org/10.1017/S0007114518001423
14. Li, J.; Wu, H.; Liu, Y.; Yang, L. High Fat Diet Induced Obesity Model Using Four Strains of Mice: Kunming, C57BL/6, BALB/c and ICR. Exp. Anim. 2020, 69(3), 326–335. https://doi.org/10.1538/expanim.19-0148
15. den Besten, G.; Bleeker, A.; Gerding, A.; van Eunen, K.; Havinga, R.; van Dijk, T.H.; Oosterveer, M.H.; Jonker, J.W.; Groen, A.K.; Reijngoud, D.J.; Bakker, B.M. Short-Chain Fatty Acids Protect Against High-Fat Diet-Induced Obesity via a PPARγ-Dependent Switch From Lipogenesis to Fat Oxidation. Diabetes 2015, 64(7), 2398–2408. https://doi.org/10.2337/db14-1213
16. Marques, C.; Meireles, M.; Norberto, S.; Leite, J.; Freitas, J.; Pestana, D.; Faria, A.; Calhau, C. High-Fat Diet-Induced Obesity Rat Model: A Comparison between Wistar and Sprague-Dawley Rat. Adipocyte 2016, 5(1), 11–21. https://doi.org/10.1080/21623945.2015.1061723
17. Alberti, K.G.M.M.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.C.; James, W.P.T.; Loria, C.M.; Smith, S.C. Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16), 1640–1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
18. Hirano, T. Pathophysiology of Diabetic Dyslipidemia. J. Atheroscler. Thromb. 2018, 25(9), 771–782. https://doi.org/10.5551/jat.RV17023
19. Ng, M.; Fleming, T.; Robinson, M.; Thomson, B.; Graetz, N.; Margono, C.; Mullany, E.C.; Biryukov, S.; Abbafati, C.; Abera, S.F.; et al. Global, Regional, and National Prevalence of Overweight and Obesity in Children and Adults during 1980–2013: A Systematic Analysis for the Global Burden of Disease Study 2013. Lancet 2014, 384(9945), 766–781. https://doi.org/10.1016/S0140-6736(14)60460-8
20. Al Zarzour, R.H.; Alshawsh, M.A.; Asif, M.; Al-Mansoub, M.A.; Mohamed, Z.; Ahmad, M.; Abdul Majid, A.M.S.; Asmawi, M.Z.; Kaur, G.; Al-Dualimi, D.W.; Yam, M.F. Adipocytokine Regulation and Antiangiogenic Activity Underlie the Molecular Mechanisms of Therapeutic Effects of Phyllanthus niruri against Non-Alcoholic Fatty Liver Disease. Nutrients 2018, 10, 1057. https://doi.org/10.3390/nu10081057
21. Al Zarzour, R.H.; Alshawsh, M.A.; Asif, M.; Al-Mansoub, M.A.; Mohamed, Z.; Ahmad, M.; Abdul Majid, A.M.S.; Asmawi, M.Z.; Kaur, G.; Al-Dualimi, D.W.; Yam, M.F. Adipocytokine Regulation and Antiangiogenic Activity Underlie the Molecular Mechanisms of Therapeutic Effects of Phyllanthus niruri against Non-Alcoholic Fatty Liver Disease. Nutrients 2018, 10, 1057. https://doi.org/10.3390/nu10081057
22. Balkrishna, A.; Gohel, V.; Kumari, P.; Manik, M.; Bhattacharya, K.; Dev, R.; Varshney, A. Livogrit Prevents Methionine-Cystine Deficiency Induced Nonalcoholic Steatohepatitis by Modulation of Steatosis and Oxidative Stress in Human Hepatocyte-Derived Spheroid and in Primary Rat Hepatocytes. Bioengineered 2022, 13(4), 10811–10826. https://doi.org/10.1080/21655979.2022.2065789
23. Hashem, M.; Hashish, E.; Atteya, M. Alleviation Harmful Effects of Non-Alcoholic Fatty Liver Disease with Phyllanthus niruri Extract in Albino Rats. Slovenian Veterinary Research 2021, 58, 121–132. https://doi.org/10.26873/SVR-1433-2021
24. Naik, A.Q.; Zafar, T.; Shrivastava, V.K. Physiological Impact of the Non-Nutritive Artificial Sweetener, Aspartame, and the Therapeutic Potential of Aqueous Extract of Phyllanthus niruri. J. Med. Food 2023, 26(7), 500–510. https://doi.org/10.1089/jmf.2022.K.0136
25. You, Y.; Zhu, F.; Li, Z.; Zhang, L.; Xie, Y.; Chinnathambi, A.; Alahmadi, T.A.; Lu, B. Phyllanthin Prevents Diethylnitrosamine (DEN) Induced Liver Carcinogenesis in Rats and Induces Apoptotic Cell Death in HepG2 Cells. Biomed. Pharmacother. 2021, 137, 111335. https://doi.org/10.1016/j.biopha.2021.111335
26. Ezzat, M.I.; Okba, M.M.; Ahmed, S.H.; El-Banna, H.A.; Prince, A.; Mohamed, S.O.; Ezzat, S.M. In-Depth Hepatoprotective Mechanistic Study of Phyllanthus niruri: In Vitro and In Vivo Studies and Its Chemical Characterization. PLoS One 2020, 15(1), e0226185. https://doi.org/10.1371/journal.pone.0226185
27. Bharati, D.; Rawat, S.; Sharma, P.; Srivastava, B. Evaluation of In Vivo Efficacy of Aqueous Leaf Extract of Phyllanthus niruri in Diabetic Hypertensive Rats. Ann. Clin. Exp. Hypertens. 2015, 3, 1031. https://doi.org/10.47739/2373-9258/1031
28. Mediani, A.; Abas, F.; Maulidiani, M.; Khatib, A.; Tan, C.P.; Ismail, I.S.; Shaari, K.; Ismail, A.; Lajis, N.H. Metabolic and Biochemical Changes in Streptozotocin Induced Obese-Diabetic Rats Treated with Phyllanthus niruri Extract. J. Pharm. Biomed. Anal. 2016, 128, 302–312. https://doi.org/10.1016/j.jpba.2016.06.003
29. Giribabu, N.; Rao, P.V.; Kumar, K.P.; Muniandy, S.; Rekha, S.S.; Salleh, N. Aqueous Extract of Phyllanthus niruri Leaves Displays In Vitro Antioxidant Activity and Prevents the Elevation of Oxidative Stress in the Kidney of Streptozotocin-Induced Diabetic Male Rats. Evid. Based Complement. Alternat. Med. 2014, 2014, 834815. https://doi.org/10.1155/2014/834815
30. Kumar, A.; Rana, A.K.; Singh, A.; Singh, A. Effect of Methanolic Extract of Phyllanthus niruri on Leptin Level in Animal Model of Diabetes Mellitus. Biomed. Pharmacol. J. 2019, 12(1), 57–63. https://doi.org/10.13005/bpj/1613
31. Mediani, A.; Abas, F.; Maulidiani, M.; Khatib, A.; Tan, C.P.; Ismail, I.S.; Shaari, K.; Ismail, A.; Lajis, N.H. Metabolic and Biochemical Changes in Streptozotocin Induced Obese-Diabetic Rats Treated with Phyllanthus niruri Extract. J. Pharm. Biomed. Anal. 2016, 128, 302–312. https://doi.org/10.1016/j.jpba.2016.06.003
32. Swargiary, D.; Kashyap, B.; Sarma, P.; Ahmed, S.A.; Gurumayum, S.; Barge, S.R.; Basumatary, D.; Borah, J.C. Free Radical Scavenging Polyphenols Isolated from Phyllanthus niruri L. Ameliorates Hyperglycemia via SIRT1 Induction and GLUT4 Translocation in In Vitro and In Vivo Models. Fitoterapia 2024, 173, 105803. https://doi.org/10.1016/j.fitote.2023.105803
33. Bhushan, V.; Bharti, S.K.; Krishnan, S.; Kumar, A.; Kumar, A. Antidiabetic Effectiveness of Phyllanthus niruri Bioactive Compounds via Targeting DPP-IV. Nat. Prod. Res. 2025, 39(12), 3426–3432. https://doi.org/10.1080/14786419.2024.2337108
34. Raji, K.A.; Afolabi, O.B.; Obafemi, O.T.; Obafemi, B.A.; Kunlere, O.E.; Emmanuel, B.O.; Obajuluwa, A.O.; Omotuyi, O.I.; Talabi, J.Y.; Lebelo, S.L.; Ntwasa, M. Polyphenolic-Rich Extract of Phyllanthus niruri (Linn.) Improves Antioxidant Status and Modulates Akt/Nrf2 and IR/Akt/GLUT2 Pathways in Streptozotocin-Induced Diabetic Rats. Nutrire 2025, 50(2), 87. https://doi.org/10.1186/s41110-025-00396-6
35. Perez-Gomez, M.V.; Bartsch, L.A.; Castillo-Rodriguez, E.; Fernandez-Prado, R.; Fernandez-Fernandez, B.; Cannata-Ortiz, P.; Ortiz, A. Clarifying the Concept of Chronic Kidney Disease for Non-Nephrologists. Clin. Kidney J. 2019, 12, 258–261. https://doi.org/10.1093/ckj/sfz007
36. Hill, N.R.; Fatoba, S.T.; Oke, J.L.; Hirst, J.A.; O’Callaghan, C.A.; Lasserson, D.S.; Hobbs, F.D.R. Global Prevalence of Chronic Kidney Disease: A Systematic Review and Meta-Analysis. PLoS ONE 2016, 11, e0158765. https://doi.org/10.1371/journal.pone.0158765
37. Banik, S.; Ghosh, A. Prevalence of Chronic Kidney Disease in Bangladesh: A Systematic Review. Int. Urol. Nephrol. 2020, 52, 661–669. https://doi.org/10.1007/s11255-020-02597-6
38. Aregawi, K.; Mekonnen, G.K.; Belete, R.; Kucha, W. Prevalence of Chronic Kidney Disease and Associated Factors among Adult Diabetic Patients: A Hospital-Based Cross-Sectional Study. Front. Epidemiol. 2024, 4. https://doi.org/10.3389/fepid.2024.1467911
39. Dehghani, A.; Alishavandi, S.; Nourimajalan, N.; Fallahzadeh, H.; Rahmanian, V. Prevalence of Chronic Kidney Diseases and Its Determinants among Iranian Adults: Results of the First Phase of Shahedieh Cohort Study. BMC Nephrol. 2022, 23. https://doi.org/10.1186/s12882-022-02832-5
40. Waikar, S.S.; Srivastava, A.; Palsson, R.; Shafi, T.; Hsu, C.-Y.; Sharma, K.; Lash, J.P.; Chen, J.; He, J.; Lieske, J.; Xie, D.; Zhang, X.; Feldman, H.I.; Curhan, G.C. Association of Urinary Oxalate Excretion with the Risk of Chronic Kidney Disease Progression. JAMA Intern. Med. 2019, 179, 542–551. https://doi.org/10.1001/jamainternmed.2018.7980
41. Cao, W.; Li, A.; Wang, L.; Zhou, Z.; Su, Z.; Bin, W.; Wilcox, C.S.; Hou, F.F. A Salt-Induced Reno-Cerebral Reflex Activates Renin-Angiotensin Systems and Promotes CKD Progression. J. Am. Soc. Nephrol. 2015, 26, 1619–1633. https://doi.org/10.1681/ASN.2014050518
42. Pamudji, R.H.G.; Navirius, F.J. Effect of Red Betel Leaf Extract (Piper crocatum) on Blood Glucose Levels and Kidney Histopathology in Streptozotocin-Nicotinamide Induced Rats. J. La Medihealtico 2023, 4, 2. https://doi.org/10.37899/journallamedihealtico.v4i3.896
43. Wei, X.; Yi, X.; Liu, J.; Sui, X.; Li, L.; Li, M.; Lv, H.; Yi, H. Circ-PHKB Promotes Cell Apoptosis and Inflammation in LPS-Induced Alveolar Macrophages via the TLR4/MyD88/NF-κB/CCL2 Axis. Respir. Res. 2024, 25, 104. https://doi.org/10.1186/s12931-024-02677-6
44. Sinha, M.; Manna, P.; Sil, P.C. Amelioration of Galactosamine-Induced Nephrotoxicity by a Protein Isolated from the Leaves of the Herb, Cajanus indicus L. BMC Complement. Altern. Med. 2007, 7, 11. https://doi.org/10.1186/1472-6882-7-11
45. Aziz, M.A.A.; Badary, D.M.; Hussein, M.R.A. Renal Damage Following Alloxan-Induced Diabetes Is Associated with Generation of Reactive Oxygen Species, Alterations of p53, TGF-β1 and Extracellular Matrix Metalloproteinases in Rats. Cell Biol. Int. 2017. https://doi.org/10.1002/cbin.10752
46. Frąk, W.; Kućmierz, J.; Szlagor, M.; Młynarska, E.; Rysz, J.; Franczyk, B. New Insights into Molecular Mechanisms of Chronic Kidney Disease. Biomedicines 2022, 10, 2846. https://doi.org/10.3390/biomedicines10112846
47. Fularski, P.; Czarnik, W.; Frankenstein, H.; Gąsior, M.; Młynarska, E.; Rysz, J.; Franczyk, B. Unveiling Selected Influences on Chronic Kidney Disease Development and Progression. Cells 2024, 13, 751. https://doi.org/10.3390/cells13090751
48. Shahbazi, F.; Doosti-Irani, A.; Soltanian, A.; Poorolajal, J. Global Trends and Projection of Aetiology-Based Chronic Kidney Disease Incidence from 1990 to 2030: A Bayesian Age-Period-Cohort Modelling Study. Epidemiol. Health 2024, e2023027. https://doi.org/10.4178/epih.e2023027
49. Mohandes, S.; Doke, T.; Hu, H.; Mukhi, D.; Dhillon, P.; Susztak, K. Molecular Pathways That Drive Diabetic Kidney Disease. J. Clin. Invest. 2023, 133, e165654. https://doi.org/10.1172/JCI165654
50. Li, M.T.; Liu, L.L.; Zhou, Q.; Huang, L.X.; Shi, Y.X.; Hou, J.B.; Lu, H.T.; Yu, B.; Chen, W.; Guo, Z.Y. Phyllanthus niruri L. Exerts Protective Effects Against the Calcium Oxalate-Induced Renal Injury via Ellagic Acid. Front. Pharmacol. 2022, 13, 891788. https://doi.org/10.3389/fphar.2022.891788
51. Sidratullah, K.P.M. Effect of Leafflower (Phyllanthus niruri Linn.) Treatment on Kidney and Uterus in Sodium Chloride-Induced Fibrotic Rats. Borneo Sci. Med. J. 2021, 5(3). https://doi.org/10.32539/bsm.v5i3.187
52. Giribabu, N.; Rao, P.V.; Kumar, K.P.; Muniandy, S.; Rekha, S.S.; Salleh, N. Aqueous Extract of Phyllanthus niruri Leaves Displays In Vitro Antioxidant Activity and Prevents the Elevation of Oxidative Stress in the Kidney of Streptozotocin-Induced Diabetic Male Rats. Evid. Based Complement. Alternat. Med. 2014, 2014, 834815. https://doi.org/10.1155/2014/834815
53. Freitas, A.M.; Schor, N.; Boim, M.A. The Effect of Phyllanthus niruri on Urinary Inhibitors of Calcium Oxalate Crystallization and Other Factors Associated with Renal Stone Formation. BJU Int. 2002, 89(9), 829–834. https://doi.org/10.1046/j.1464-410X.2002.02794.x
54. Da’i, M.; Wahyuni, A.S.; Trisharyanti, I.; Azizah, T.; Suhendi, A.; Saifudin, A. Antioxidant Activity of Phyllanthus niruri L. Herbs: In Vitro and In Vivo Models and Isolation of Active Compound. Natl. J. Physiol. Pharm. Pharmacol. 2016, 6(1), 32–37. https://doi.org/10.5455/njppp.2015.5.0510201575
55. Shanmugam, B.; Shanmugam, K.R.; Ravi, S.; Subbaiah, G.V.; Ramakrishana, C.; Mallikarjuna, K.; Reddy, K.S. Hepatoprotective Activity of Phyllanthus niruri against Liver Damage. Pharmacogn. Mag. 2017. https://doi.org/10.4103/0973-1296.203973
56. Yuniarti, W.M.; Lukiswanto, B.S. Altered Liver and Renal Serum Marker Enzymes in Alloxan Induced Diabetic Rats Treated with Phyllanthus niruri. J. Appl. Environ. Biol. Sci. 2016, 6(12), 94–98.
57. Luo, F.; Yu, Y.; Li, M.; Chen, Y.; Zhang, P.; Xiao, C.; Lv, G. Polymeric Nanomedicines for the Treatment of Hepatic Diseases. J. Nanobiotechnol. 2022, 20, 488. https://doi.org/10.1186/s12951-022-01708-y
58. O'Mara, S.R.; Gebreyes, K. Hepatic Disorders. In Tintinalli's Emergency Medicine: A Comprehensive Study Guide, 8th ed.; McGraw-Hill: New York, NY, USA, 2016; p. 525.
59. Tamber, S.S.; Bansal, P.; Sharma, S.; Singh, R.B.; Sharma, R. Biomarkers of Liver Diseases. Mol. Biol. Rep. 2023, 50, 7815–7823. https://doi.org/10.1007/s11033-023-08666-0
60. Sivakrishnan, S. Liver Disease Overview. World J. Pharm. Pharm. Sci. 2019, 8, 1385–1395
61. Seitz, H.K.; Bataller, R.; Cortez-Pinto, H.; Gao, B.; Gual, A.; Lackner, C.; Mathurin, P.; Mueller, S.; Szabo, G.; Tsukamoto, H. Alcoholic Liver Disease. Nat. Rev. Dis. Primers 2018, 4, 16. https://doi.org/10.1038/s41572-018-0014-7
62. Loomba, R.; Friedman, S.L.; Shulman, G.I. Mechanisms and Disease Consequences of Nonalcoholic Fatty Liver Disease. Cell 2021, 184, 2537–2564. https://doi.org/10.1016/j.cell.2021.04.015
63. Fadlallah, H.; El Masri, D.; Bahmad, H.F.; Abou-Kheir, W.; El Masri, J. Update on the Complications and Management of Liver Cirrhosis. Med. Sci. 2025, 13, 13. https://doi.org/10.3390/medsci13010013
64. Chen, Y.; Chen, R.; Li, H.; Shuai, Z. Clinical Management of Autoimmune Liver Diseases: Juncture, Opportunities, and Challenges Ahead. Immunol. Res. 2025, 73, 67. https://doi.org/10.1007/s12026-025-09622-9
65. Kodoli, R.S.; Galatage, S.T.; Killedar, S.G.; Pishwikar, S.A.; Habbu, P.V.; Bhagwat, D.A. Hepatoprotective Activity of Phyllanthus niruri Linn. Endophytes. Future J. Pharm. Sci. 2021, 7, 97. https://doi.org/10.1186/s43094-021-00243-1
66. Hashem, M.; Hashish, E.; Atteya, M. Alleviation Harmful Effects of Non-Alcoholic Fatty Liver Disease with Phyllanthus niruri Extract in Albino Rats. Slovenian Vet. Res. 2021, 58, 121–132. https://doi.org/10.26873/SVR-1433-2021
67. Dey, D.; Chaskar, S.; Bhatt, N.; Chitre, D. Hepatoprotective Activity of BV-7310, a Proprietary Herbal Formulation of Phyllanthus niruri, Tephrosia purpurea, Boerhavia diffusa, and Andrographis paniculata, in Alcohol-Induced HepG2 Cells and Alcohol Plus a Haloalkane, CCl4-Induced Liver Damage in Rats. Evid.-Based Complement. Altern. Med. 2020, 2020, 6428906. https://doi.org/10.1155/2020/6428906
68. Khanth, S.P.E.; Mishra, A.; Mandal, S.; Chawla, S.; Kalra, B.S. Hepatoprotective Potential of Phyllanthus niruri and Andrographis paniculata in Isoniazid-Rifampicin Induced Hepatotoxicity in Rats. Indian J. Tuberc. 2023. https://doi.org/10.1016/j.ijtb.2023.12.009
69. Simarmata, T.A.; Yulizal, O.; Sopacua, E. Effect of Combination of Snakehead Fish Extract (Channa striata), Meniran (Phyllanthus niruri L.), and Temulawak (Curcuma xanthorrhiza) on Histopathological and Liver Function of Rats Model Diabetes Mellitus with High Fat Diet. J. Health Sains 2024, 5, 829–844. https://doi.org/10.46799/jhs.v5i11.1391
70. Khandia, R.; Pathe, C.S.; Vishwakarma, P.; Dhama, K.; Munjal, A. Evaluation of the Ameliorative Effects of Phyllanthus niruri on the Deleterious Insecticide Imidacloprid in the Vital Organs of Chicken Embryos. J. Ayurveda Integr. Med. 2020, 11, 495–501. https://doi.org/10.1016/j.jaim.2019.03.003
71. Khamis, A.; Abdalla, O.; Hashem, M.; Abdelnaeim, N. Comparative Effects of Phyllanthus niruri and Plantago major in Carbon Tetrachloride Intoxicated Rats. Adv. Anim. Vet. Sci. 2022, 10, 1444–1450. https://doi.org/10.17582/journal.aavs/2022/10.7.1444.1450
72. Naik, A.Q.; Zafar, T.; Shrivastava, V.K. Physiological Impact of the Non-Nutritive Artificial Sweetener, Aspartame, and the Therapeutic Potential of Aqueous Extract of Phyllanthus niruri. J. Med. Food 2023, 26, 500–510. https://doi.org/10.1089/jmf.2022.K.0136
73. Al Zarzour, R.H.; Alshawsh, M.A.; Asif, M.; Al-Mansoub, M.A.; Mohamed, Z.; Ahmad, M.; Abdul Majid, A.M.S.; Asmawi, M.Z.; Kaur, G.; Al-Dualimi, D.W.; Yam, M.F. Adipocytokine Regulation and Antiangiogenic Activity Underlie the Molecular Mechanisms of Therapeutic Effects of Phyllanthus niruri against Non-Alcoholic Fatty Liver Disease. Nutrients 2018, 10, 1057. https://doi.org/10.3390/nu10081057
74. Balakrishnan, P.; Toms, T. Hepato Protective Effect of Phyllanthus niruri in CCl4 Induced Hepatic Damage in Mus musculus. Eur. J. Biomed. 2018, 5, 819–824.
75. Shanmugam, B.; Shanmugam, K.R.; Ravi, S.; Subbaiah, G.V.; Ramakrishana, C.; Mallikarjuna, K.; Reddy, K.S. Hepatoprotective Activity of Phyllanthus niruri against Liver Damage. Pharmacogn. Mag. 2017. https://doi.org/10.4103/0973-1296.203973
76. Manonmani, N.; Ramar, M.; Geetha, N.; Arasu, M.V.; Erusan, R.; Sowmiya, J.J. Hepatoprotective Activity of Aqueous Extract of Phyllanthus niruri in CCl4 Induced Liver Toxicity: In Vivo Study. Res. J. Biotechnol. 2015, 10, 11–17.
77. Novianto, A.; Nurrochmad, A.; Sari, I.P.; Astuti, P. Hepatoprotective Effect of Combination of Curcuma domestica Val. and Phyllanthus niruri Linn. against Paracetamol-Induced Liver Damage in Wistar Rats. Int. J. Pharm. Clin. Res. 2015, 7, 450–457.
78. Ramamurthy, V.; Rajakumar, R. Studies on Ethanolic Leaf Extract of Phyllanthus niruri and Its Effect on Aflatoxin Intoxicated Male Albino Rats. Int. J. Zool. Appl. Biosci. 2016, 1, 1–6.
79. Singh, A.; Hegde, S. Aging and Inflammation. Cold Spring Harb. Perspect. Med. 2023.
80. Mainous, A.G., III; Sharma, P.; Jo, A. Systemic Inflammation among Adults with Diagnosed and Undiagnosed Cardiometabolic Conditions: A Potential Missed Opportunity for Cardiovascular Disease Prevention. Front. Med. 2024, 11. https://doi.org/10.3389/fmed.2023.1327205
81. Liu, S.; Yang, R.; Zuo, Y.; Qiao, C.; Jiang, W.; Cheng, W.; Wei, W.; Liu, Z.; Geng, Y.; Dong, Y. The Association of Circulating Systemic Inflammation with Premature Death and the Protective Role of the Mediterranean Diet: A Large Prospective Cohort Study of UK Biobank. BMC Public Health 2024, 24, 18888. https://doi.org/10.1186/s12889-024-18888-x
82. Mehrzadi, S.; Khalili, H.; Fatemi, I.; Malayeri, A.; Siahpoosh, A.; Goudarzi, M. Zingerone Mitigates Carrageenan-Induced Inflammation Through Antioxidant and Anti-Inflammatory Activities. Inflammopharmacology 2021, 29, 127–139. https://doi.org/10.1007/s10753-020-01320-y
83. Page, M.J.; Bester, D.; Pretorius, E. The Role of Lipopolysaccharide-Induced Cell Signalling in Chronic Inflammation. Chronic Stress 2022, 6.
84. Wei, X.; Yi, X.; Liu, J.; Sui, X.; Li, L.; Li, M.; Lv, H.; Yi, H. Circ-PHKB Promotes Cell Apoptosis and Inflammation in LPS-Induced Alveolar Macrophages via the TLR4/MyD88/NF-κB/CCL2 Axis. Respir. Res. 2024, 25, 104. https://doi.org/10.1186/s12931-024-02677-6
85. Sutrisna, E.; Maryati; Wahyuni, S.; Azizah, T. Anti-Inflammatory Effect of Phyllanthus niruri L. from Indonesia (Pre-Clinical Study). Pharmacogn. J. 2019, 11(6). https://doi.org/10.5530/pj.2019.11.208
86. Mostofa, R.; Ahmed, S.; Begum, M.M.; Rahman, M.S.; Begum, T.; Ahmed, S.U.; Tuhin, R.H.; Das, M.; Hossain, A.; Sharma, M.; Begum, R. Evaluation of Anti-Inflammatory and Gastric Anti-Ulcer Activity of Phyllanthus niruri L. (Euphorbiaceae) Leaves in Experimental Rats. BMC Complement. Altern. Med. 2017, 17(1), 267. https://doi.org/10.1186/s12906-017-1771-7
87. Palupi, D.; Sugiarti, L.; Yulianti, E. Analgesic Activity Combination of Dry Extract of Meniran Leaves (Phyllanthus niruri L.) and Moringa Leaves (Moringa oleifera L.) Using the Chemical Induction Method: In Vivo Study. Nat. Sci. Eng. Technol. J. 2024, 4, 299–307. https://doi.org/10.37275/nasetjournal.v4i1.53
88. Islam, M.S.; Hossain, M.S.; Shaha, H.K.; Shipa, S.J.; Ahmed, F.; Saqueeb, N. Antibacterial, Antioxidant, Anti-Inflammatory and Anti-Diarrheal Potentiality Evaluation of Whole Plant Extract of Phyllanthus niruri L. Bangladesh J. Sci. Ind. Res. 2024, 59(4), 195–202. https://doi.org/10.3329/bjsir.v59i4.74975
89. Jeje, T.O.; Onodugo, C.A.; Oladipo, G.O.; Ibukun, E.O.; Umoh, U. Anti-Inflammatory Assessment of the Aqueous Extract of Phyllanthus niruri in Wistar Rats. FUOYE J. Pure Appl. Sci. 2024, 9(2), 121–140. https://doi.org/10.55518/fjpas.YPCF1525
90. Sowjanya, K.; Girish, C.; Bammigatti, C.; Lakshmi, N.C.P. Efficacy of Phyllanthus niruri on Improving Liver Functions in Patients with Alcoholic Hepatitis: A Double-Blind Randomized Controlled Trial. Indian J. Pharmacol. 2021, 53(6), 448–456. https://doi.org/10.4103/ijp.IJP_540_20
91. Abu Hassan, M.R.; Md Said, R.H.; Zainuddin, Z.; Omar, H.; Md Ali, S.M.; Aris, S.A.; Chan, H.K. Effects of One-Year Supplementation with Phyllanthus niruri on Fibrosis Score and Metabolic Markers in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Heliyon 2023, 9(6), e16652. https://doi.org/10.1016/j.heliyon.2023.e16652
92. Shaker, M.K.; Hassany, M.; Eysa, B.; Adel, A.; Zidan, A.; Mohamed, S. The Activity of a Herbal Medicinal Product of Phyllanthus niruri and Silybum marianum Powdered Extracts (Heptex®) in Patients with Apparent Risk Factors for Nonalcoholic Steatohepatitis: A Phase II, Multicentered, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. BMC Complement. Med. Ther. 2025, 25(1), 8. https://doi.org/10.1186/s12906-024-04692-y
93. Ananthathandavan, P.; Balavigneshwaran, A.; Vijayakumar, T.M.; Rajesh, N.A.; Na, R.; Pavithra, A.; Sumitha, A. Efficacy and Safety of BoozLiv™ as an Add-On Therapy in Patients with Alcoholic Liver Disease: An Open-Label, Randomized Controlled Trial. Gastroenterol. Endosc. 2024, 2(4), 168–175. https://doi.org/10.1016/j.gande.2024.07.007
94. Kumar, S.; Gupta, A.; Revadekar, M.; More, S.; Kulkarni, A.N.; Borkar, S.S. Efficacy and Safety of Hepano Tablet in Liver Disorder Patients with Abnormal Liver Function Test: A Randomized Active-Controlled Prospective Clinical Study. Drug Dev. Ther. 2017, 8(1), 6–12. https://doi.org/10.4103/ddt.DDT_12
95. Shaker, M.K.; Hassany, M.; Eysa, B.; Adel, A.; Zidan, A.; Mohamed, S. The Activity of a Herbal Medicinal Product of Phyllanthus niruri and Silybum marianum Powdered Extracts (Heptex®) in Patients with Apparent Risk Factors for Nonalcoholic Steatohepatitis: A Phase II, Multicentered, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. BMC Complement. Med. Ther. 2025, 25(1), 8. https://doi.org/10.1186/s12906-024-04692-y
96. Sowjanya, K.; Girish, C.; Bammigatti, C.; Lakshmi, N.C.P. Efficacy of Phyllanthus niruri on Improving Liver Functions in Patients with Alcoholic Hepatitis: A Double-Blind Randomized Controlled Trial. Indian J. Pharmacol. 2021, 53(6), 448–456. https://doi.org/10.4103/ijp.IJP_540_20
97. Abu Hassan, M.R.; Md Said, R.H.; Zainuddin, Z.; Omar, H.; Md Ali, S.M.; Aris, S.A.; Chan, H.K. Effects of One-Year Supplementation with Phyllanthus niruri on Fibrosis Score and Metabolic Markers in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Heliyon 2023, 9(6), e16652. https://doi.org/10.1016/j.heliyon.2023.e16652Figures
Author Affiliation
Department of Pharmaceutical Sciences, North South University, Dhaka, Bangladesh
ARTICLE INFO
Dr. Raushanara Akter, Professor, School of Pharmacy, Brac University, Bangladesh
Dr. Md. Ashraful Alam, Professor, Department of Pharmaceutical Sciences, North South University, Bangladesh
